Kura Oncology (KURA) and Kyowa Kirin announced topline results from KOMET-001, the Phase 2 registration-directed trial of ziftomenib, a highly selective, once-daily, oral investigational menin ...
The enhanced partnership provides enterprise-wide access to AlphaMeld Corporation’s proprietary AI-powered AlphaMeld ® platform, further accelerating Kyowa Kirin’s innovative drug discovery ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback